English

Interim report Vigmed Holding AB (publ) January – June 2016

Report this content

Second quarter: 1 April – 30 June 2016

  • Sales for the second quarter amounted to SEK 0.7 (0.5) million.
  • Operating result in the second quarter amounted to SEK -8.4 (-8.7) million.
  • Cash flow from operating activities during the second quarter amounted to SEK     -9.2 (-8.1) million.
  • On 30 June 2016 cash and cash equivalents amounted to SEK 44.1 (31.8) million.

First six months: January - June 2016

  • Sales for the first six months amounted to SEK 2.8 (2.0) million.
  • Operating result for the first six months amounted to SEK -15.4 (-17.7) million.
  • Cash flow from operating activities during the first six months amounted to SEK - 20.0 (-26.8) million.
  • On 30 June 2016 cash and cash equivalents amounted to SEK 44.1 (31.8) million.

 Significant events during the second quarter

During the second quarter, Vigmed has continued to win smaller tenders and has intensified the interaction with distributors in countries where procurement procedures are expected to begin during next year.

Vigmed’s products have received the highest ranking in quality tests conducted by independent parties in the procurement processes that have been under way in the first six months of this year.

The company’s operating profit and cash flow are improving as a result of the ongoing efforts in managing cost reduction and cost-control.

In April 2016 the Board of Vigmed Holding AB (publ) appointed Henrik Olsen as CEO of the company. Since autumn 2015 he has served as acting CEO.

At the Annual General Meeting held on 12 May 2016 Sten Dahlborg was elected as new Board member and Chairman of the company. Lennart Holm, Lennart Dreyer and Per Knutsson declined re-election and left the Board. Furthermore, the General Meeting authorised the Board to issue new shares. The number of shares to be issued shall be a maximum of 7,305,555, which corresponds to a dilution of about 10 % of the registered share capital at the time for the utilisation of the authorisation.

For further information contact:

Chairman of the Board Sten Dahlborg, +46 708-369 419

CEO Henrik Olsen, +46 763-497 364

This information is information that Vigmed Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 8.00 am CET on August 25, 2016.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

For further information contact:

Chairman of the board, Sten Dahlborg + 70 836 9419 or CEO, Henrik Olsen +46 76 349 7364

Vigmed is a Swedish medical technology company whose mission is to eliminate needlestick injuries and the associated risk of cross infections with blood-borne infectious diseases by offering the market unique needle-protected products. Vigmed is headquartered in Helsingborg, Sweden. Vigmed’s share is traded on NASDAQ OMX First North in Stockholm (ticker VIG) and has approximately 5 600 shareholders. Remium Nordic AB is the Company’s Certified Advisor. Additional information about the company can be found on Vigmed’s website: www.vigmed.com/investor

Documents & Links